(New York, USA) DelveInsight’s ‘Respiratory Syncytial Virus Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Respiratory Syncytial Virus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Respiratory Syncytial Virus pipeline domain.
Request a sample and discover the recent breakthroughs happening in the Respiratory Syncytial Virus pipeline landscape @ Respiratory Syncytial Virus Pipeline Outlook
Key Takeaways from the Respiratory Syncytial Virus Pipeline Report
- DelveInsight’s Respiratory Syncytial Virus Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Respiratory Syncytial Virus treatment.
- The leading Respiratory Syncytial Virus companies include GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others are evaluating their lead assets to improve the Respiratory Syncytial Virus treatment landscape.
- Key Respiratory Syncytial Virus pipeline therapies in various stages of development include Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others.
- In May 2023, GSK announced the clearance of Arexvy, a vaccine against the respiratory syncytial virus (RSV), by the US Food and Drug Administration, making it the world’s first vaccination of its kind.
- In May 2023, Ascletis Pharma Inc. reported that the China National Medical Products Administration (“NMPA”) has approved a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV) infection.
Respiratory Syncytial Virus Overview
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infection, especially in youngsters. By the age of four, nearly all children have been infected, with many infected during their first year of life. Because infection does not offer complete immunity, reinfection is common, albeit usually less severe. Outbreaks are most common in the winter and early spring. RSV is the most prevalent cause of lower respiratory tract infection in young infants, accounting for more than 50,000 hospitalizations in children under the age of five in the United States each year. The initial infection frequently proceeds from an upper respiratory tract disease with congestion and fever to the lower respiratory tract, causing bronchiolitis and, in rare cases, pneumonia with cough and difficulty breathing. Later infections often exclusively affect the upper respiratory tract. Children who have suffered bronchiolitis are more prone to develop asthma as they grow older.
Find out more about Respiratory Syncytial Virus medication @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Respiratory Syncytial Virus Treatment Analysis: Drug Profile
Nirsevimab (MEDI-8897): MedImmune
MEDI8897 is a monoclonal antibody (mAb) used to prevent lower respiratory tract sickness (LRTI) caused by respiratory syncytial virus (RSV), which is the most common cause of LRTI in newborns and young children. It is currently in phase III of development.
Sisunatovir: ReViral
Sisunatovir is an orally given fusion inhibitor that works by preventing RSV F-mediated fusion with the host cell. Preclinical studies revealed that sisunatovir has a low toxicity profile and a promising therapeutic index. Sisunatovir demonstrated excellent exposure in Phase 1 clinical investigations, with no significant side effects recorded. In 2018, the findings of Phase 2a challenge research in healthy adult volunteers revealed that sisunatovir reduced viral load and clinical symptoms statistically significantly. ReViral has begun two international multicenter Phase 2 clinical trials of sisunatovir in high-risk pediatric and adult patient populations.
Key Respiratory Syncytial Virus Therapies and Companies
- Nirsevimab (MEDI-8897): MedImmune
- Sisunatovir: ReViral
- MVA-BN-RSV Vaccine: Bavarian Nordic
- RSVpreF (PF-06928316): Pfizer
- VAC 18193 (Ad26.RSV.preF): Janssen
- mRNA-1345: Moderna
Learn more about the novel and emerging Respiratory Syncytial Virus pipeline therapies @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Respiratory Syncytial Virus Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Request for Sample Report @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Scope of the Respiratory Syncytial Virus Pipeline Report
- Coverage: Global
- Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
- Key Respiratory Syncytial Virus Pipeline Therapies: Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others.
Dive deep into rich insights for drugs used for Respiratory Syncytial Virus treatment; visit @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Table of Contents
1. Introduction
2. Executive Summary
3. Respiratory Syncytial Virus Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Respiratory Syncytial Virus Pipeline Therapeutics
6. Respiratory Syncytial Virus Pipeline: Late Stage Products (Phase III)
7. Respiratory Syncytial Virus Pipeline: Late Stage Products (Phase III)
8. Respiratory Syncytial Virus Pipeline: Mid-Stage Products (Phase II)
9. Respiratory Syncytial Virus Pipeline: Early Stage Products (Phase I)
10. Respiratory Syncytial Virus Therapeutic Assessment
11. Inactive Respiratory Syncytial Virus Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Respiratory Syncytial Virus Companies
14. Key Respiratory Syncytial Virus Products
15. Respiratory Syncytial Virus Unmet Needs
16. Respiratory Syncytial Virus Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting